Clinical Trials Directory

Trials / Completed

CompletedNCT00351091

Risedronate in Postmenopausal Women With Low Bone Density

a Six Month, Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group Study to Estimate the Pharmacodynamic Response of Two Risedronate Regimens Compared With 5mg Daily : 150mg Monthly Dose for Six Months and 15mg Daily for Thirty Days Followed by 150mg Monthly Dose for 5 Months in Postmenopausal Women With Low Bone Density.

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
150 (actual)
Sponsor
Sanofi · Industry
Sex
Female
Age
65 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this pilot study is to estimate the percent change from baseline at Week 4, Month 6 in NTX bone turnover marker for a monthly 150mg dose of risedronate administered for 6 months and a loading dose regimen of risedronate over a 6 month treatment period both compared to a 5 mg daily dose of risedronate for 6 months The secondary objectives are : * To estimate the percent change from baseline at specified visits other than Week 4, Month 6 in NTX for the monthly 150 mg dose of risedronate administered for 6 months and the loading dose regimen of risedronate over a 6 month treatment period both compared to the 5 mg daily dose of risedronate. * To estimate the percent change from baseline at all specified visits in serum CTX and bone specific alkaline phosphatase for the monthly 150 mg dose of risedronate administered for 6 months and the loading dose regimen of risedronate over a 6 month treatment period both compared to the 5 mg daily of risedronate. * To estimate the percent change from baseline at Month 6 in lumbar spine BMD for the monthly 150 mg dose of risedronate administered for 6 months and the loading dose regimen of risedronate over a 6 month treatment period both compared to the 5 mg daily dose of risedronate. * To evaluate the safety of the risedronate 150 mg monthly and the loading dose regimen.

Conditions

Interventions

TypeNameDescription
DRUGRISEDRONATE

Timeline

Start date
2002-11-01
Primary completion
2003-06-01
Completion
2003-06-01
First posted
2006-07-12
Last updated
2012-02-17

Source: ClinicalTrials.gov record NCT00351091. Inclusion in this directory is not an endorsement.